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Differential Effect of Intracoronary Infusion of Mobilized
Peripheral Blood Stem Cells by Granulocyte
Colony–Stimulating Factor on Left Ventricular Function
and Remodeling in Patients With Acute Myocardial
Infarction Versus Old Myocardial Infarction
The MAGIC Cell-3-DES Randomized, Controlled Trial
Hyun-Jae Kang, MD; Hae-Young Lee, MD; Sang-Hoon Na, MD; Sung-A Chang, MD;
Kyung-Woo Park, MD; Hyung-Kwan Kim, MD; Song-Yi Kim, MD; Ho-Joon Chang, MD; Whal Lee, MD;
Won Jun Kang, MD; Bon-Kwon Koo, MD; Yong-Jin Kim, MD; Dong Soo Lee, MD; Dae-Won Sohn, MD;
Kyou-Sup Han, MD; Byung-Hee Oh, MD; Young-Bae Park, MD; Hyo-Soo Kim, MD
Background—The efficacy of intracoronary infusion of granulocyte colony-stimulating factor (G-CSF) mobilized
peripheral blood stem cells (PBSCs) has not been compared between patients with acute (AMI) versus old myocardial
infarction (OMI). In addition, the potential risk of restenosis associated with G-CSF–based stem cell therapy has not
been evaluated in the setting of drug eluting stent (DES) implantation.
Methods and Results—We randomly allocated 96 patients with myocardial infarction who underwent coronary
revascularization with DES for the culprit lesion into 4 groups. Eighty-two patients completed 6-month follow-up; AMI
cell infusion (n25), AMI control (n25), OMI cell infusion (n16), and OMI control group (n16). In cell infusion
groups, PBSCs were mobilized by G-CSF for 3 days and delivered to infarcted myocardium via intracoronary infusion.
The AMI cell infusion group showed a significant additive improvement in left ventricular ejection fraction (LVEF) and
remodeling compared with controls (change of LVEF: 5.19.1% versus 0.28.6%, P0.05; change of end-systolic
volume: 5.417.0 mL versus 6.521.9 mL, P0.05). In OMI patients, however, there was no significant change of
LVEF and ventricular remodeling in spite of significant improvement of coronary flow reserve after cell infusion.
G-CSF–based cell therapy did not aggravate neointimal growth with DES implantation.
Conclusions—Intracoronary infusion of mobilized PBSCs with G-CSF improves LVEF and remodeling in patients with
AMI but is less definite in patients with OMI. G-CSF–based stem cell therapy with DES implantation is both feasible
and safe, eliminating any potential for restenosis. (Circulation. 2006;114[suppl I]:I-145–I-151.)
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Recent clinical studies1–6 reported favorable effects of stemcell transplantation in patients with acute myocardial in-
farction (AMI). However, the outcome has not been adequately
evaluated in old myocardial infarction (OMI) patients. Granulo-
cyte colony-stimulating factor (G-CSF)–based stem cell therapy
has been proposed as a practical and noninvasive alternative to
stem cell therapy using bone marrow stem cells. Because G-CSF
alone has only shown equivocal benefits in previous clinical
trials,5,7,8 G-CSF might be considered mostly as a mobilizer to
enrich peripheral blood stem cells (PBSCs). Despite the potential
adverse effects increasing vascular events,9–11 short-term use of
G-CSF in patients with myocardial infarction (MI) seems safe.
Previously, we reported that, in patients with MI, intra-
coronary infusion of PBSCs improved cardiac function and
exercise capacity, whereas the administration of G-CSF alone
did not.5 Additionally, we suggested the possibility of aggra-
vated restenosis after G-CSF administration. Therefore, in the
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Infarction With G-CSF and Intra-Coronary Stem Cell
Infusion-3-Drug Eluting Stents (MAGIC Cell-3-DES) Trial,
we adopted the exclusive use of drug eluting stents (DES) and
modified the timing of G-CSF treatment to minimize the risk
of restenosis and inflammation. This trial was performed to
evaluate the safety of G-CSF–based stem cell therapy and to
compare outcome of intracoronary infusion of mobilized
PBSCs between patients with AMI and OMI.
Methods
Patients and Protocol
The MAGIC Cell-DES trial was designed as a randomized, con-
trolled trial to recruit 100 patients with AMI and OMI (Figure 1). In
this study, AMI was defined as randomization within 14 days from
onset of new ST-segment elevation infarction, and OMI was defined
as a randomization later than 14 days from onset. Patients who were
successfully revascularized with DES in the culprit lesion were
eligible for enrollment. Exclusion criteria were: (1) persistent severe
heart failure (left ventricular ejection fraction [LVEF] 20%); (2)
uncontrolled myocardial ischemia or ventricular tachycardia; (3)
culprit lesion of infarct related artery not feasible for percutaneous
coronary intervention (PCI) or unsuccessful PCI; (4) age 80 years;
(5) malignancy; (6) serious current infection or hematologic disease;
and (7) life expectancy 1 year.
After revascularization, patients were randomly assigned by use of
a randomization table. After randomization, study processes were not
blinded. The study protocol was approved by the Institutional
Review Board of Seoul National University Hospital. Informed
written consents were obtained from patients after explaining the
procedure and risk of the study.
The primary end point to evaluate efficacy was the change in
LVEF, measured by MRI. The secondary end points were changes in
left ventricle (LV) volume, myocardial perfusion measured by
coronary flow reserve (CFR), and the development of major adverse
cardiac events ([MACE] death, new MI, revascularization, or hos-
pitalization because of aggravation of ischemia or heart failure). We
calculated that we would need 20 patients in each group to detect a
difference in global LVEF change of 7%, with an 80% power and a
2-sided significance level of P0.05. We adjusted the sample size
for an estimated follow-up loss rate of 25%, which results in 25
patients in each group.
Stem Cell Mobilization, Characterization, and
Intracoronary Infusion
In the cell infusion groups after successful PCI, PBSCs were
mobilized by daily subcutaneous injections of G-CSF (Dong-A
Pharmaceutical) at 10 g/kg body weight for 3 days. At day 4,
mobilized PBSCs were collected with COBE spectra apheresis
system (COBE BCT Inc) using the mononuclear cell collection
methods. The infusion cell doses were 1 to 2109 monocytes per
patients to guarantee the minimum target cell dose of 7106 CD34
cells. We evaluated the composition of mobilized cells by flow
cytometry with anti-VEGFR2, anti-CD34, and anti-AC133 antibod-
ies (Santa Cruz Biotechnology Inc). We infused PBSCs selectively
to infarcted myocardium via over-the-wire balloon catheter as
described previously.5 Placebo was not applied to the control group.
Cardiac MRI
Cardiac MRI (Sonata 1.5T, Siemens) was performed after PCI at
baseline and at 6 months. Short axis cine images with a thickness of
8 mm and a gap of 2 mm were acquired throughout the entire LV
using contiguous 2D steady state precession sequences. After intra-
venous application of gadolinium-diethylene-triamine penta-acetate,
late enhancement (LE) imaging was performed with phase-sensitive
inversion recovery sequence.12 Using the ARGUS software (Sie-
mens), LVEF, LV volumes, and volume of LE were calculated.
Angiography, CFR, and Quantitative
Coronary Angiography
Coronary angiograms were obtained at initial PCI and 6-month
follow-up. Quantitative coronary angiography (QCA) was performed
by an independent blinded specialist with a Quantcor QCA V4.0
program (Pie Medical Imaging). Binary restenosis was defined as a
diameter stenosis 50% within the stented segments including
Figure 1. Study protocol.
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5-mm segments from stent margin. CFR was calculated as the ratio
of hyperemic to baseline coronary blood flow velocity using a
Doppler guide wire (Flowire, Volcano Corp) at 1 cm distal to the
implanted stent. CFR was measured at baseline and at 6-month
follow-up at the same site as described previously.5
Clinical Safety and Follow-Up Visits
To study the safety of G-CSF–based stem cell therapy, the devel-
opment of MACE; clinical status including G-CSF–related pain,
dyspnea, and chest pain; and biochemical tests including creatine
kinase (CK)-MB, C-reactive protein (CRP), and blood cell counts,
were evaluated during admission and follow-up visits scheduled at 1,
3, and 6 months.
Statistical Analysis
Continuous variables were presented as meanSD. Categorical
variables were compared with the 2 test. Statistical comparisons of
continuous variables between initial and follow-up data were per-
formed using a paired t test for comparison for intragroup compar-
isons and a Student’s t test for intergroup comparisons. Statistical
significance was assumed at a value of P0.05. Statistical analysis
was performed with SPSS (version 13.0, SPSS Inc).
The authors had full access to the data and take responsibility for
its integrity. All of the authors have read and agreed to the article as
written.
Results
Since January 2004, 96 patients were enrolled and random-
ized into 4 groups: enrolled patients were stratified by the
presence or absence of AMI and randomly assigned into the
cell infusion and control group, respectively. Enrollment of
the OMI group was stopped prematurely because of unlike-
lihood of achieving a significant difference in the primary end
point (improvement of LVEF). Among them, 82 patients
completed 6-month follow-up (Figure 1). The baseline char-
acteristics of the participants who completed the follow-up
evaluation are summarized in Table 1. Clearly, the time to
randomization from onset of infarction was quite different
between AMI an OMI groups (7.01.0 versus 517525
days).
Procedural Safety and Clinical Follow-Up
There were no serious adverse reactions related to G-CSF
administration during the periprocedural period. Six patients
(14.6%) complained of transient G-CSF–related adverse ef-
fects: bone pain (n2), headache (n2), injection site ten-
derness (n1), and dizziness (n1). During G-CSF injection
and hospitalization, we did not observe any aggravation of
ischemia or thrombotic complications. Systemic inflamma-
tion as measured by CRP was not significantly different
between the cell infusion and control group in the decline of
CRP from baseline to day 4 in AMI (P0.05). However, in
OMI patients, G-CSF slightly but significantly increased CRP












Age, y 60.610.6 59.412.3 59.89.7 60.16.8
Sex (male) 20 (80%) 20 (80%) 15 (94%) 13 (81%)
Body mass index, kg/m2 24.63.3 23.83.1 25.03.5 24.21.8
Risk factors
Hypertension 15 (60%) 9 (36%) 9 (56%) 5 (31%)
Diabetes mellitus 5 (20%) 7 (28%) 6 (38%) 7 (44%)
Hyperlipidemia 6 (24%) 3 (12%) 4 (25%) 7 (44%)
Previous myocardial infarction 1 (4%) 0 (0%) 16 (100%) 16 (100%)
Smoking 12 (48%) 11 (44%) 4 (25%) 3 (19%)
PCI situation
Infarct related artery (LAD:LCx:RCA) 13:1:11 10:3:12 11:1:4 11:2:3
Extent (1-:2-:3-vessel disease) 14:8:3 12:9:4 6:7:3 5:3:8
Primary reperfusion 12 (48%) 16 (64%) — —
Time to primary reperfusion, h 9.97.8 8.47.1 — —
Chronic total occlusion — — 6 (38%) 10 (63%)
Time to revascularization, days 4.03.1 3.94.4 514524 960832
Stent used (Cypher:Taxus) 19:6 17:8 14:2 12:4
Medication
Aspirinclopidogrel 25 (100%) 25 (100%) 16 (100%) 16 (100%)
ACE inhibitor/AT-II receptor blocker 25 (100%) 23 (92%) 16 (100%) 15 (94%)
-Blocker 22 (88%) 21 (84%) 14 (88%) 16 (100%)
Statin 18 (72%) 19 (76%) 12 (75%) 10 (63%)
There were no significant differences in any of the baseline parameters between the cell infusion and control group
either with AMI or OMI. LAD indicates left anterior descending artery; LCx, left circumflex artery; RCA, right coronary
artery; ACE, angiotensin converting enzyme; AT, angiotensin.
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in the cell infusion group (0.560.38 to 1.300.77 mg/dL;
P0.001) compared with the control group (0.550.33 to
0.500.40 mg/dL; P0.05).
We infused 1.40.5109 collected leukocytes (volume:
7.83.2 mL) via over-the-wire balloon angioplasty catheter
after PCI into the infarcted myocardium in patients from the
cell infusion group. The composition of the mobilized and
infused cells were: 9.310.2% CD34, 15.115.9%
KDR, 2.27.4% AC133, and 5.710.4% CD34/
KDR. Notably, the infused cells in AMI patients contained
more KDR cells (19.418.4% versus 9.710.3%;
P0.05) and marginally more CD34/KDR cells
(8.012.7% versus 2.02.6%; P0.062) than those in OMI
patients. There was no evidence for myocardial damage
associated with cell therapy, as measured by CK-MB levels
(P0.05). There was no procedure-related serious adverse
reactions during apheresis and cardiac catheterization. Also,
there was no MACE during the hospitalization.
A total of 5 patients dropped out before 6-month follow-
up; 1 patient in the AMI cell infusion group and 3 patients in
the AMI control group moved to different hospitals, and 1
patient in the AMI cell infusion group was dropped because
he could not visit the outpatient clinic because of severe
degenerative arthritis. We monitored the general conditions
of all of the patients by telephone, and none experienced
serious adverse effects. There were 2 mortalities; 1 patient in
the AMI control group because of reinfarction at 1 month and
1 patient in the OMI cell infusion group because of panperi-
tonitis at 2 months after enrollment. In addition, 2 patients (1
each from the AMI control and OMI control group) experi-
enced target vessel revascularization at 6-month follow-up.
LV Systolic Function, Infarct Volume, and
Remodeling by MRI
Baseline LVEF and LV volume were similar among study
groups (Tables 2 and 3). AMI patients at 6 months showed
significant improvement in LVEF compared with baseline in
the cell infusion group (52.09.9% to 57.28.7%; P0.01),
and the change in LVEF was significantly greater in the cell
infusion compared with the control group (5.19.1% ver-
sus 0.28.6%; P0.046; Figure 2A). LV end-systolic
volume was significantly decreased in the AMI cell infusion
group compared with the AMI control group (5.417.0 mL
versus 6.521.9 mL; P0.04). Moreover, LE volume
decreased significantly in the AMI cell infusion group com-
pared with the AMI control group (12.513.3 mL versus
0.814.3 mL; P0.01). In OMI patients, however, there
were no significant longitudinal changes of LVEF, LV
volume, or LE volume in both the cell infusion and control
group (Figure 2B).
CFR
After stenting, baseline CFR measured in the culprit artery
was similar between the cell infusion and control group in
both AMI and OMI patients. At follow-up, there was a
significant increase in CFR in both groups of AMI patients,
whereas only the cell infusion group showed significant
improvement in OMI patients (P0.01; Tables 2 and 3).
Angiographic Follow-Up
At 6 months, only 4 patients in the control group (2 each in
AMI and OMI) showed angiographic binary restenosis. The
late luminal loss was not significantly different between the
cell infusion and control group, suggesting that G-CSF
administration and stem cell infusion after DES implantation
did not aggravate neointimal growth (Figure 3). QCA analy-
sis of the distal nonstented segment also showed no signifi-
cant difference in late luminal loss between the 2 groups.
Discussion
The 6-month follow-up result of the MAGIC Cell-3-DES trial
showed that intracoronary infusion of mobilized PBSCs with
G-CSF improved LV systolic function and remodeling pref-
erentially in patients with AMI, whereas its effect on LV
TABLE 2. Comparison of MRI and Doppler Parameters in Patients With AMI
MRI
Cell Infusion Control
Baseline Follow-Up P Value Baseline Follow-Up P Value
LVEF, % 52.09.9 57.18.7 0.01 53.213.3 53.111.5 0.93
LV end-diastolic volume, mL 143.127.2 146.527.6 0.41 129.828.0 139.942.7 0.11
LV end-systolic volume, mL 69.021.5 63.520.3 0.13 62.730.9 69.238.0 0.16
Late enhancement volume, mL 40.516.8 28.016.8 0.01 45.530.5 46.332.3 0.81
Coronary flow reserve 1.590.55 2.480.63 0.01 1.600.42 2.350.58 0.01
TABLE 3. Comparison of MRI and Doppler Parameters in Patients With OMI
MRI
Cell Infusion Control
Baseline Follow-Up P Value Baseline Follow-Up P Value
LVEF, % 48.512.9 48.512.7 0.99 45.110.2 45.311.0 0.92
LV end-diastolic volume, mL 171.054.0 176.248.9 0.62 171.354.6 173.447.8 0.70
LV end-systolic volume, mL 90.944.8 94.545.2 0.70 96.036.7 97.438.1 0.74
Late enhancement volume, mL 44.829.5 39.322.8 0.06 43.229.8 44.735.0 0.74
Coronary flow reserve 1.970.60 2.700.88 0.01 1.940.72 2.100.80 0.69
I-148 Circulation July 4, 2006
 at CONS KESLI on June 17, 2014http://circ.ahajournals.org/Downloaded from 
systolic function in those with OMI was insignificant. We
also reconfirmed the safety and feasibility of intracoronary
infusion of G-CSF–mobilized PBSCs in patients with AMI
and OMI. Furthermore, restenosis after G-CSF therapy and
cell infusion, previously suggested from the results of the
original MAGIC Cell-1 trial,5 was not observed in this study
using DES.
Influences of Stem Cell Therapy on LV Function,
Remodeling, and Microcirculation
The LVEF increased by an absolute 5.19.1% at 6 months
after intracoronary PBSC infusion in patients with AMI.
However, in patients with OMI, we could not find any
significant improvements in LV systolic function after cell
therapy. The improvement observed in AMI was comparable
with other studies,2,13 as well as our previous study.5 How-
ever, results in OMI patients were different from other studies
that showed significant improvement of the LVEF with
recanalization of chronic occlusion followed by PBSC14 or
bone marrow cell15 infusion. The discrepancy between our
results and others may be related to cell types and extent of
hibernating myocardium. The study by Erbs et al14 used
similar strategies to ours but showed quite different outcomes
in change of LV systolic function, which might be related to
differences in baseline characteristics of patients. In OMI
patients of our study, CFR was improved, and infarct volume
in MRI tended to decrease with cell infusion as Erbs’ group
did,14 which suggests that the disparity in the extent of
hibernating myocardium in peri-infarcted segments may be
related to the difference in recovery of contractility. In
addition, duration of chronic total occlusion was shorter in
patients from Erbs’ study14 compared with our study. In
subgroup analysis of our patients with chronic total occlusion,
cell infusion did not improve LVEF after recanalization
(n6). Strauer et al15 injected bone marrow cells, which are
Figure 2. Changes in LVEF between
baseline and 6-month follow-up. A, In
AMI patients, the cell infusion group
showed significant improvement of LVEF
from baseline to 6-month follow-up,
whereas the control group did not. When
absolute changes in LVEF were com-
pared between 2 groups, the difference
was statistically significant (P0.046). B,
In OMI patients, there was no significant
difference in changes of LVEF at
follow-up in both groups. *Small dots
show data for individual patients; large
dots show mean values. Vertical bars
show SD.
Figure 3. Late loss of minimal luminal diameter at 6-month
follow-up. There was no significant difference in loss of MLD
from postintervention to 6-month follow-up between the cell
infusion and control group, and this resulted in no difference in
occurrence of restenosis at follow-up. *Small dots show data for
individual patients; horizontal lines show mean values. MLD indi-
cates minimal luminal diameter.
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known to include more mesenchymal stem cells than PBSCs,
and thus may have more potential for myocardial regenera-
tion resulting in favorable influence on OMI.
It has still not been clarified what mechanism accounts for
improvement of ventricular function after stem cell transplan-
tation after MI. We can guess at least 2 possibilities: (1) direct
differentiation of infused stem cell; and (2) paracrine effects
by infused cell, which stimulate resident cardiac stem cells to
proliferate and differentiate into cardiac or vascular cells.
However, the relative contribution of 2 mechanisms could not
be determined.
Angiogenesis has been regarded as a plausible mechanism
for the prevention of remodeling and rescue of hibernating
myocardium.16,17 In our study, cell infusion improved coro-
nary microcirculation of infarct-related artery to a greater
extent compared with the control group. In OMI, improve-
ment of CFR was significantly greater in the cell infusion
group than the control group, although it was insignificant in
AMI. The disparity may come from mechanisms of improv-
ing microcirculation. In AMI, resolution of “microvascular
stunning” because of microthrombi or tissue edema associ-
ated with acute infarction itself and revascularization18 is
more important than cell therapy. However, in OMI, CFR
mainly reflects the effect of cell therapy and revasculariza-
tion. Thus, preferential improvement of CFR in the OMI cell
infusion group suggests a beneficial effect of cell therapy on
coronary perfusion.
In addition to angiogenesis, several potential mechanisms,
such as myogenesis, rejuvenation by cell fusion, and para-
crine effects, have been postulated to affect remodeling after
stem cell therapy. In our study, improvement of LV systolic
function and remodeling cannot be explained by the extent
and presence of hibernating myocardium alone. This suggests
that mechanisms other than angiogenesis may be involved.
Infarct size measured as LE in MRI was reduced by cell
infusion significantly in AMI, although marginally in OMI
patients. This finding suggests that cell therapy may induce
not only angiogenesis but also myogenesis, that is, angiomyo-
genesis, leading to reduction of infarct size.
G-CSF itself has several potential mechanisms that can
favorably influence the outcome of stem cell therapy.19,20 More-
over, G-CSF showed enhanced endothelial progenitor cell
colony-forming ability and increased chemokine receptor ex-
pression important for progenitor cell homing and engraftment.21
Different Outcomes of Stem Cell Therapy in
AMI Versus OMI
We evaluated PBSC distribution 4 hours after intracoronary
coinfusion of 2-[18F]-fluoro-2-deoxy-D-glucose–labeled
PBSCs in 16 patients and observed that 1.60.7% of the
labeled PBSCs were detected in the infarcted myocardium
(data not shown), which is similar to another study with bone
marrow cells.22 Despite a different outcome with cell infu-
sion, integration of infused stem cell is not different between
patients with AMI and with OMI, suggesting that the inter-
action of underlying milieu and integrated stem cells after
entrapment during the first pass after infusion may play an
important role in outcome. The finding that the cells mobi-
lized in AMI patients contained more stem/progenitor cells
might be one possible explanation for preferential improve-
ment of LV systolic function in AMI patients. However, the
characteristics of the cells mobilized by G-SCF might be
more responsible for the difference. Because PBSCs contain
mainly more endothelial progenitor cells than mesenchymal
stem cells, angiogenesis would contribute more in our
study.23 In OMI, mostly infarcted myocardium is replaced by
scar, allowing little room for improvement by angiogenesis,
explaining the minimal effect of stem cell therapy on con-
tractile function in OMI. However, in AMI, acute ischemia
upregulates various stimuli that induce differentiation and
homing of stem cell,24,25 which may enhance the outcome of
stem cell therapy. Our results suggest that stem cell therapy
should be optimized according to the underlying condition of
patients suffering from LV dysfunction.
Safety and Feasibility of G-CSF Mobilized Stem
Cell Infusion Combined With DES
We previously observed higher rates of restenosis in patients
treated with G-CSF.5 G-CSF treatment was associated with
greater late luminal loss and higher restenosis, especially
when injected before PCI. In our previous study, G-CSF–
mediated neointimal growth was associated with mobilization
of smooth muscle progenitor cells and inflammation induced
by G-CSF.26 In this situation, DES was effective to prevent
neointimal growth aggravated by G-CSF, and G-CSF in turn
facilitated re-endothelialization of DES.26 We also reported
the beneficial effect of stem cell mobilization to enhance
re-endothelialization with vascular brachytherapy.27 There-
fore, we expected that the combination of DES and G-CSF
would be safe and effective. With this combination, neointi-
mal growth was not worse in patients who received G-CSF
than control or previous studies using DES without stem
cells.28 Additionally, cell infusion mobilized by G-CSF also
did not aggravate de novo atherosclerotic lesions.
During follow-up, we observed 3 cases of MACE only in
the control group (1 fatal MI and 2 cases of target vessel
revascularization). G-CSF–based stem cell therapy was safe
and feasible in patients with MI.
Conclusions
Six-month follow-up result of the MAGIC Cell-3-DES Trial
shows that intracoronary infusion of mobilized PBSCs by
G-CSF significantly improves LV systolic function and
reduces infarct size, compared with those receiving only PCI,
in patients with AMI. Such efficacy of cell therapy is less
definite in patients with OMI in spite of enhanced coronary
perfusion, which needs further larger study. G-CSF adminis-
tration with the exclusive use of DES in stem cell therapy is
both feasible and safe and may eliminate any potential for
restenosis suggested from previous studies.
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